PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
|Articles|September 19, 2011
Gateway 2011: Corden Pharma
Advertisement
Corden Pharma
Otto-Hahn-Strasse
68723 Plankstadt, Germany
Phone: +49 6202 99-2299
Fax: +49 6202 99-2000
E-mail:
Website:
General Company Company Description:
Corden Pharma is a specialized contract manufacturer utilizing sophisticated technologies developed through years of proven experience that are ideal for the production of oral and sterile highly potent or antibiotic pharmaceutical products and their active ingredients.
We offer customised service packages which span the entire pharmaceutical product continuum from development and manufacturing of Active Pharmaceuticals Ingredients, formulation development, assistance with approval procedures, and commercial production of Drug Products, all the way to complete pharmaceutical logistics.
Our plants, located across Europe and in the US, are audited by all relevant approval authorities, making Corden Pharma a premier partner for pharmaceutical companies worldwide.
Visit Corden Pharma at CPhI booth 31B04 and/or AAPS booth 1524 to discover the services, technologies and products which distinguish Corden Pharma as a Full-Service Development and Contract Manufacturer:
- Custom API Manufacturing
- Generic API Manufacturing
- Drug Product Development and Manufacturing
- Generic Dossier Development
- Formulation Capabilities
- Packaging
- Clinical Supply Services
- Specialized Technologies, including High Potent APIs and Peptides
- Readily Available Excipients, Building Blocks and Generic Bulk APIs
Contact:
[email protected] arrange meetings for AAPS
Advertisement
Related to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
2
FDA's IND Pilot Puts CMC Review First
3
Spray Drying Capacity Signals Faster Paths for Poorly Soluble Drugs
4
Mature Medicines Divestment Signals Shift in Manufacturing Strategy
5